Bioidentical hormone therapy

Julia A. Files, Marcia G. Ko, Sandhya Pruthi

Research output: Contribution to journalReview article

44 Scopus citations

Abstract

The change in hormonal milieu associated with perimenopause and menopause can lead to a variety of symptoms that can affect a woman's quality of life. Postmenopausal hormone therapy (HT) is an effective, well-tolerated treatment for these symptoms. However, combined HT consisting of conjugated equine estrogen and medroxyprogesterone acetate has been associated with an increased number of health risks when compared with conjugated equine estrogen alone or placebo. As a result, some women are turning to alternative hormonal formulations known as compounded bioidentical HT because they perceive them to be a safer alternative. This article defines compounded bioidentical HT and explores the similarities and differences between it and US Food and Drug Administration-approved HT. We will examine the major claims made by proponents of compounded bioidentical HT and recommend strategies for management of patients who request bioidentical HT from physicians.

Original languageEnglish (US)
Pages (from-to)673-680
Number of pages8
JournalMayo Clinic proceedings
Volume86
Issue number7
DOIs
StatePublished - Jul 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bioidentical hormone therapy'. Together they form a unique fingerprint.

  • Cite this